RCM
RLAY icon

Ratan Capital Management’s Relay Therapeutics RLAY Stock Holding History

Ratan Capital Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-40,500
Closed -$667K – 32
2023
Q1 		$667K Buy
+40,500
New +$726K 1.77% 14

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Ratan Capital Management's RLAY Position: Q1 2022 in Review

Ratan Capital Management sold out of Relay Therapeutics (RLAY) in Q1 2022, closing a stake of 50,000 shares — an estimated $1.54M sold.

Ratan Capital Management first reported a position in RLAY in Q3 2020 and held it in 6 quarters. The position peaked at $3.63M in Q1 2021. 140 funds tracked by Wall St. Rank hold RLAY as of Q1 2022.

  • Ratan Capital Management reported no remaining Relay Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Ratan Capital Management sold 50,000 Relay Therapeutics shares in Q1 2022, an estimated $1.54M.
  • Ratan Capital Management first reported a position in Relay Therapeutics in Q3 2020 and held it in 6 quarters.
  • Ratan Capital Management's Relay Therapeutics position peaked at $3.63M in Q1 2021.
  • 140 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2022.

Based on Ratan Capital Management's 13F filing for Q1 2022, filed 16 May 2022.